Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
D000469:Alkaline Phosphatase / Q000097:blood; D000686:Amyloidosis / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000209:etiology; D001780:Blood Coagulation Tests; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005170:Factor X / Q000378:metabolism; D005171:Factor X Deficiency / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006529:Hepatomegaly / Q000097:blood / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use*; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D005723:gamma-Glutamyltransferase / Q000097:blood
D003907:Dexamethasone; D004317:Doxorubicin; D005170:Factor X; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D008558:Melphalan